Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Ahmet Aydin to Humans

This is a "connection" page, showing publications Ahmet Aydin has written about Humans.

 
Connection Strength
 
 
 
0.572
 
  1. Biben E, Menon L, Gokden N, Spond MF, Eichhorn JM, Aydin AM. Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report. BMC Urol. 2023 Dec 08; 23(1):204.
    View in: PubMed
    Score: 0.039
  2. Aydin SG, Olmez OF, Selvi O, Geredeli C, Ozden F, Bilici A, Acikgoz O, Karci E, Kutlu Y, Hamdard J, Aydin A. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data. J Gastrointest Cancer. 2024 Mar; 55(1):227-236.
    View in: PubMed
    Score: 0.037
  3. Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):453.e19-453.e26.
    View in: PubMed
    Score: 0.035
  4. Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 04; 40(4):164.e1-164.e7.
    View in: PubMed
    Score: 0.033
  5. Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021; 12:628063.
    View in: PubMed
    Score: 0.032
  6. Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May; 94:107481.
    View in: PubMed
    Score: 0.032
  7. Aydin AM, Chakiryan NH, Spiess PE. Will Dynamic Sentinel Lymph Node Biopsy Become the New International Standard for Evaluating High-risk Penile Cancer in Patients with Clinically Negative Lymph Nodes? Eur Urol. 2020 12; 78(6):873-874.
    View in: PubMed
    Score: 0.031
  8. Aydin AM, Chahoud J, Adashek JJ, Azizi M, Magliocco A, Ross JS, Necchi A, Spiess PE. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020 10; 17(10):555-570.
    View in: PubMed
    Score: 0.031
  9. Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 10; 27(10):882-889.
    View in: PubMed
    Score: 0.031
  10. Aydin AM, Baydar DE, Hazir B, Babaoglu B, Bilen CY. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020 Oct; 38(10):2537-2545.
    View in: PubMed
    Score: 0.029
  11. Aydin AM, Cheriyan S, Spiess PE. Treating advanced penile cancer: where do we stand in 2019? Curr Opin Support Palliat Care. 2019 09; 13(3):249-254.
    View in: PubMed
    Score: 0.029
  12. Aydin AM, Pow-Sang JM. Editorial Comment. J Urol. 2019 06; 201(6):1125-1126.
    View in: PubMed
    Score: 0.028
  13. Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S. Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy. Ann Nucl Med. 2019 May; 33(5):326-332.
    View in: PubMed
    Score: 0.028
  14. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov; 37(11):2419-2427.
    View in: PubMed
    Score: 0.028
  15. Aydin AM, Eldem G, Peynircioglu B, Baydar DE, Bilen CY. Local recurrence of renal cell carcinoma that simulated multiple renal arteriovenous fistulas after laparoscopic partial nephrectomy: Report of a rare case. Int J Urol. 2016 10; 23(10):888-891.
    View in: PubMed
    Score: 0.023
  16. Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mul? J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 05; 8(3):784-793.
    View in: PubMed
    Score: 0.008
  17. Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mul? J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021; 16(4):e0245415.
    View in: PubMed
    Score: 0.008
  18. Hajiran A, Azizi M, Aydin AM, Chakiryan NH, Peyton CC, Boulware DC, Manley BJ, Gilbert SM, Sexton WJ. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol. 2021 Jul; 28(7):3648-3655.
    View in: PubMed
    Score: 0.008
  19. Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mul? J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 04; 204(1):96-106.
    View in: PubMed
    Score: 0.008
  20. Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.008
  21. Hajiran A, Zemp L, Aydin AM, Cheryian SK, Pow-Sang JM, Chahoud J, Spiess PE. Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. Urol Oncol. 2021 01; 39(1):72.e1-72.e5.
    View in: PubMed
    Score: 0.008
  22. Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan; 205(1):100-108.
    View in: PubMed
    Score: 0.008
  23. Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A. Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020 10 01; 126(19):4362-4370.
    View in: PubMed
    Score: 0.008
  24. Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma? J Urol. 2020 06; 203(6):1147-1155.
    View in: PubMed
    Score: 0.007
  25. Ceyhan E, Ileri F, Ceylan T, Aydin AM, Dogan HS, Tekgul S. Predictors of Recurrence and Complications in Pediatric Pyeloplasty. Urology. 2019 04; 126:187-191.
    View in: PubMed
    Score: 0.007
  26. Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. Eur Urol Oncol. 2018 08; 1(3):242-251.
    View in: PubMed
    Score: 0.007
  27. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul; 36(7):343.e1-343.e8.
    View in: PubMed
    Score: 0.007
  28. Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology. 2018 02; 112:103-111.
    View in: PubMed
    Score: 0.006
  29. Boegemann M, Aydin AM, Bagrodia A, Krabbe LM. Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017 11; 17(11):1417-1431.
    View in: PubMed
    Score: 0.006
  30. Aki FT, Aydin AM, Dogan HS, Donmez MI, Erkan I, Duzova A, Topaloglu R, Tekgul S. Does lower urinary tract status affect renal transplantation outcomes in children? Transplant Proc. 2015 May; 47(4):1114-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.